Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double‐blind, placebo‐controlled trial

Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid... KeypointsWe have assessed if GERD‐recommended treatment with PPI (dose and duration) can significantly reduce the signs and symptoms of LPR and comorbid CRS.Treating patients with LPR and comorbid CRS with omeprazole 20 mg OD for 8 weeks significantly reduced both subjective and objective signs and symptoms of LPR and comorbid CRS when compared to placebo.However in most patients (>75%) on active treatment, signs and symptoms were still present at the end of the trial suggesting the need to find the appropriate dose and duration of treatment..INTRODUCTIONChronic rhinosinusitis (CRS) is in the realm of scientific interest, as its aetiology and association with other respiratory and multimorbid disorders have not yet been clarified. It is a public health concern as between 10% and 30% of the adult population suffer from CRS. In patients with CRS, one should rule out or treat allergies, asthma or other underlying conditions as infections, inflammation associated with environmental factors, anatomic alterations or a combination of the mentioned. Latest literature proposes laryngopharyngeal reflux (LPR) as the underlying contributory factor for chronic inflammation in both upper and lower airways. The mechanism leading to airways mucous membrane damage is still not fully understood, but chemical injury induced by low http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Otolaryngology Wiley

Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms: Randomised, double‐blind, placebo‐controlled trial

Loading next page...
 
/lp/wiley/eight-weeks-of-omeprazole-20-mg-significantly-reduces-both-sVlYM0Uqux
Publisher
Wiley
Copyright
© 2018 John Wiley & Sons Ltd
ISSN
1749-4478
eISSN
1749-4486
D.O.I.
10.1111/coa.13005
Publisher site
See Article on Publisher Site

Abstract

KeypointsWe have assessed if GERD‐recommended treatment with PPI (dose and duration) can significantly reduce the signs and symptoms of LPR and comorbid CRS.Treating patients with LPR and comorbid CRS with omeprazole 20 mg OD for 8 weeks significantly reduced both subjective and objective signs and symptoms of LPR and comorbid CRS when compared to placebo.However in most patients (>75%) on active treatment, signs and symptoms were still present at the end of the trial suggesting the need to find the appropriate dose and duration of treatment..INTRODUCTIONChronic rhinosinusitis (CRS) is in the realm of scientific interest, as its aetiology and association with other respiratory and multimorbid disorders have not yet been clarified. It is a public health concern as between 10% and 30% of the adult population suffer from CRS. In patients with CRS, one should rule out or treat allergies, asthma or other underlying conditions as infections, inflammation associated with environmental factors, anatomic alterations or a combination of the mentioned. Latest literature proposes laryngopharyngeal reflux (LPR) as the underlying contributory factor for chronic inflammation in both upper and lower airways. The mechanism leading to airways mucous membrane damage is still not fully understood, but chemical injury induced by low

Journal

Clinical OtolaryngologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off